{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008556","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.766467+00:00","generated_at":"2026-06-01T09:47:41.224710+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Scholar Rock initiates Phase 2 EMBRAZE obesity trial; SRK-439 preclinical data shows superiority over anti-ActRII","bullets":["Phase 2 EMBRAZE proof-of-concept trial initiated for apitegromab in obesity, targeting 100 subjects on GLP-1 RA; primary data expected mid-2025.","Preclinical head-to-head: SRK-439 at 1 mg/kg preserved lean mass equivalent to anti-ActRII at 20 mg/kg; all doses showed superiority.","Loan Amendment No. 4 extends interest-only period to May 2025, modifies milestones for $25M additional tranche available through Dec 2024.","SRK-439 attenuated lean mass loss to 4.2% at 10 mg/kg vs. 14.1% with IgG control + semaglutide in DIO mice.","Company hosts Investor Day; anticipates IND filing for SRK-439 in 2025 after EMBRAZE results."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008556","json":"https://secwatch.observer/filing/0001558370-24-008556.json","markdown":"https://secwatch.observer/filing/0001558370-24-008556.md","text":"https://secwatch.observer/filing/0001558370-24-008556.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024008556/0001558370-24-008556-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024008556/srrk-20240517x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:47:41.224710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}